CA - Knight Therapeutics GAAP EPS of -C$0.13 revenue of C$81.66M; issues FY23 guidance

2023-03-23 08:36:05 ET

• Knight Therapeutics press release ( OTCPK:KHTRF ): Q4 GAAP EPS of -C$0.13.
• Revenue of C$81.66M (+40.1% Y/Y).
• For the quarter ended December 31, 2022, gross margin as a percentage of revenues was 45% compared to 48% in the same prior year period.
• Outlook: For fiscal 2023, Knight expects to report C$280 to C$300 million in revenue and adjusted EBITDA, as a percentage of revenues, between 13% to 15% of revenue. The guidance is based on a number of assumptions, including but not limited to the following: no revenues for business development transactions not completed as of March 22, 2023

For further details see: